Vincenzo Adamo
A5054443196- Lung Cancer Treatments and Mutations
- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Advanced Breast Cancer Therapies
- Cancer Genomics and Diagnostics
- Lung Cancer Diagnosis and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Cancer Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
- Bone health and treatments
- Inflammatory Biomarkers in Disease Prognosis
- Peptidase Inhibition and Analysis
- Genetic factors in colorectal cancer
- Colorectal Cancer Surgical Treatments
- Medical Imaging and Pathology Studies
- Monoclonal and Polyclonal Antibodies Research
- Estrogen and related hormone effects
- Head and Neck Cancer Studies
- Pancreatic and Hepatic Oncology Research
- Neuroendocrine Tumor Research Advances
- Radiopharmaceutical Chemistry and Applications
Azienda Ospedaliera Ospedali Riuniti Papardo Piemonte
2014-2024
Federico II University Hospital
2024
University of Naples Federico II
2024
University of Ferrara
2024
University of Messina
2014-2023
CTO Andrea Alesini
2023
Azienda Ospedaliera Universitaria Policlinico "G. Martino"
2006-2021
Collaborative Group (United States)
2021
Istituto Ortopedico Gaetano Pini
2016-2017
Azienda Sanitaria Locale CN2
2017
To evaluate whether two commonly used newer platinum-based regimens offer any advantage over vinorelbine-cisplatin (reference regimen) in response rate for patients with advanced non-small-cell lung cancer (NSCLC).Chemotherapy-naive were randomized to receive gemcitabine 1,250 mg/m(2) days 1 and 8 plus cisplatin 75 day 2 every 21 (GC arm), or paclitaxel 225 (3-hour infusion) then carboplatin (area under the concentration-time curve of 6 mg/mL x min), both on (PCb vinorelbine 25 mg/m(2)/wk 12...
Abstract Biological changes that occur during metastatic progression of breast cancer are still incompletely characterized. In this study, we compared intrinsic molecular subtypes and gene expression in 123 paired primary tissues from patients. Intrinsic subtype was identified using a PAM50 classifier χ2 tests determined the differences variable distribution. The rate conversion 0% basal-like tumors, 23.1% HER2-enriched (HER2-E) 30.0% luminal B 55.3% A tumors. 40.2% cases, tumors converted...
Immune-inflammatory biomarkers (IIBs) showed a prognostic relevance in patients with metastatic CRC (mCRC). We aimed at evaluating the power of new comprehensive biomarker, Pan-Immune-Inflammation Value (PIV), mCRC receiving first-line therapy.In present pooled-analysis, we included enrolled Valentino and TRIBE trials. PIV was calculated as: (neutrophil count × platelet monocyte count)/lymphocyte count. A cut-off determined using maximally selected rank statistics method. Generalised boosted...
Background Concomitant medications, such as steroids, proton pump inhibitors (PPI) and antibiotics, might affect clinical outcomes with immune checkpoint inhibitors. Methods We conducted a multicenter observational retrospective study aimed at evaluating the impact of concomitant medications on outcomes, by weighing their associations baseline characteristics (including performance status, burden disease body mass index) underlying causes for prescription. This analysis included consecutive...
Background Some concomitant medications including antibiotics (ATB) have been reproducibly associated with worse survival following immune checkpoint inhibitors (ICIs) in unselected patients non-small cell lung cancer (NSCLC) (according to programmed death-ligand 1 (PD-L1) expression and treatment line). Whether such relationship is causative or associative matter of debate. Methods We present the outcomes analysis according baseline (prior ICI initiation) putative immune-modulatory effects...
PURPOSE: To compare gemcitabine and cisplatin (GC) with mitomycin, ifosfamide, (MIC) chemotherapy in patients stage IIIB (limited to T4 for pleural effusion N3 supraclavicular lymph nodes) or IV non–small-cell lung cancer (NSCLC). The end points were the evaluation of quality life (QoL), response rates, survival, toxicity. PATIENTS AND METHODS: Three hundred seven randomized receive either 1,000 mg/m 2 on days 1, 8, 15 plus 100 day 2, every 28 days, mitomycin 6 , ifosfamide 3,000 mesna 1...
PURPOSE The nucleoside analog, gemcitabine, has shown activity as a single agent in the treatment of metastatic non-small-cell lung cancer (NSCLC). Its combination with cisplatin preclinical models suggested synergy between two drugs. aim study was to evaluate clinical efficacy and toxicity cisplatin-gemcitabine advanced NSCLC. PATIENTS AND METHODS Forty-eight consecutive previously untreated NSCLC patients entered trial from January June 1994. median age 60 years (range, 37 70) performance...
From February 1983 to January 1985, 497 patients with advanced breast cancer were randomly allocated receive either epirubicin or doxorubicin in the following combination chemotherapy regimen: fluorouracil (5-FU) 500 mg/m2 intravenous (IV) on days 1 and 8; 50 IV day 1; cyclophosphamide (FEC FAC). Cycles repeated every 21 until progression cumulative doses of 700 for 550 doxorubicin. Dose reductions applied according standard criteria. Activity was evaluated 443 (222 FEC arm 221 FAC arm). The...
Genistein aglycone improves bone metabolism in women. However, questions about the long-term safety of genistein on breast as well its continued efficacy still remain.We assessed profile and endometrium effects after 3 yr therapy.The parent study was a randomized, double-blind, placebo-controlled trial involving 389 osteopenic, postmenopausal women for 24-months. Subsequently, subcohort (138 patients) therapy an additional year.Participants received 54 mg daily (n = 71) or placebo 67). Both...
Abstract We conducted a large, multicenter, retrospective survey aimed to explore the impact of tumor bone involvement in Non-Small Cell Lung Cancer.Data on clinical-pathology, skeletal outcomes and bone-directed therapies for 661 deceased patients with evidence metastasis were collected statistically analyzed. Bone metastases evident at diagnosis 57.5% patients. In remaining cases median time appearance was 9 months. Biphosphonates administered 59.6% Skeletal-related events experienced by...
Pemetrexed has been widely used in patients with advanced non-small cell lung cancer (NSCLC). The clinical relevance of polymorphisms folate pathway genes for pemetrexed metabolism have not fully elucidated yet. aim this study was to evaluate the expression levels circulating miR-22, miR-24, and miR-34a, possibly involved pathway, NSCLC treated compared healthy controls investigate their impact on patient outcomes. A total 22 consecutive NSCLC, pemetrexed-based chemotherapy 27 age sex...
Nivolumab is a novel therapeutic option in NSCLC, associated with significant survival gain compared Docetaxel. However, predictive biomarkers are lacking. The presence of systemic inflammation has been correlated poor outcome many cancer types. We aimed to evaluate whether there correlation between some indicators and response or Docetaxel pre‐treated NSCLCs. Data 62 patients receiving were analyzed. Baseline neutrophilia thrombocytosis not response. High dNLR was no Nivolumab, but...
Few studies are available on the role of maintenance strategies after induction treatment regimens based anti-epidermal growth factor receptors, and optimal regimen for an receptors-based in patients with RAS wild-type metastatic colorectal cancer is still to be defined.To determine whether therapy single-agent panitumumab was noninferior plus fluorouracil leucovorin a 4-month regimen.This open-label, randomized phase 2 noninferiority trial conducted from July 7, 2015, through October 27,...
PURPOSE We assessed the prognostic/predictive role of primary tumor sidedness and uncommon alterations anti–epidermal growth factor receptor (EGFR) resistance (primary in RAS BRAF wild-type metastatic colorectal cancer patients treated with anti-EGFR monoclonal antibodies [PRESSING] panel) RAS/ (wt) (mCRC) who were randomly assigned to panitumumab plus fluorouracil, leucovorin, oxaliplatin (FOLFOX-4) induction followed by maintenance or without fluorouracil (FU) leucovorin (LV); Valentino...
Radiomics is defined as the use of automated or semi-automated post-processing and analysis multiple features derived from imaging exams. Extracted might generate models able to predict molecular profile solid tumors. The aim this study was develop a predictive algorithm define mutational status EGFR in treatment-naïve patients with advanced non-small cell lung cancer (NSCLC). CT scans 109 NSCLC (21 EGFR-mutant 88 EGFR-wild type) underwent radiomics machine learning model recognize EGFR-WT...
Abstract Background Immune-checkpoint inhibitors (ICIs) changed the therapeutic landscape of patients with lung cancer. However, only a subset them derived clinical benefit and evidenced need to identify reliable predictive biomarkers. Liquid biopsy is non-invasive repeatable analysis biological material in body fluids promising tool for cancer biomarkers discovery. In particular, there growing evidence that extracellular vesicles (EVs) play an important role tumor progression tumor-immune...
COVID-19 has disrupted the global health care system since March 2020. Lung cancer (LC) patients (pts) represent a vulnerable population highly affected by pandemic. This multicenter Italian study aimed to evaluate whether outbreak had an impact on access diagnosis and treatment of LC pts compared with pre-pandemic time.Consecutive newly diagnosed referred 25 Oncology Departments between December 2020 were included. Access rate temporal intervals date symptoms onset diagnostic therapeutic...